Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04580420 · ClinicalTrials.gov registry record · Phase 2

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

A Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
18
Study locations

NCT04580420 is a Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1 that is actively recruiting participants, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 28 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 18 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04580420, a Phase 2 study of End Stage Renal Disease and Primary Hyperoxaluria Type 1, is actively recruiting participants, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
18
Study locations

Study Summary

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Conditions Studied

End Stage Renal Disease Primary Hyperoxaluria Type 1

Interventions

  • DRUG DCR-PHXC

Study Locations (18)

Other

  • Clinical Trial Site - Bron
  • Clinical Trial Site - Paris
  • Clinical Trial Site - Bonn
  • Clinical Trial Site - Heidelberg
  • Clinical Trial Site - Roma
  • Clinical Trial Site - Beirut
  • Clinical Trial Site - Casablanca
  • Clinical Trial Site - Oradea
  • Clinical Trial Site - Oradea
  • Clinical Trial Site - Barcelona
  • Clinical Trial Site - Santa Cruz de Tenerife
  • Clinical Trial Site - Dubai
  • Clinical Trial Site - London
  • Clinical Trial Site - London

California

  • Clinical Trial Site - San Francisco

Massachusetts

  • Clinical Trial Site - Boston

Minnesota

  • Clinical Trial Site - Rochester

New York

  • Clinical Trial Site - New York

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-04-15
Est. Completion 2032-01-30
Phase Phase 2

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04580420

The ClinicalTrials.gov registry entry for NCT04580420 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which DCR-PHXC is the first listed.

NCT04580420 reports 18 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04580420 about?

NCT04580420 is a clinical study titled "Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD". The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

What is the current status of trial NCT04580420?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-04-15. Estimated completion is 2032-01-30.

What conditions does trial NCT04580420 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Primary Hyperoxaluria Type 1.

What interventions are being tested in trial NCT04580420?

The interventions under investigation include: DCR-PHXC (DRUG).

Who is sponsoring clinical trial NCT04580420?

This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04580420 being conducted?

This trial has 18 study locations across California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

End Stage Renal Disease

All registered trials for this condition

Primary Hyperoxaluria Type 1

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.